×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IDYA – ideaya biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IDYA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/14
07:44 pm
idya
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial [Yahoo! Finance]
Medium
Report
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial [Yahoo! Finance]
12/11
06:27 am
idya
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma [Yahoo! Finance]
12/11
06:00 am
idya
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
Low
Report
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
12/10
06:42 am
idya
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers [Yahoo! Finance]
12/10
06:00 am
idya
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
Low
Report
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
12/4
07:20 pm
idya
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance [Yahoo! Finance]
Low
Report
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance [Yahoo! Finance]
12/4
07:00 pm
idya
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Low
Report
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
12/4
07:00 pm
idya
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Low
Report
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/12
04:06 pm
idya
Form 8-K IDEAYA Biosciences, Inc. For: Dec 09
Low
Report
Form 8-K IDEAYA Biosciences, Inc. For: Dec 09
12/5
04:19 pm
idya
Form 8-K IDEAYA Biosciences, Inc. For: Dec 04
Low
Report
Form 8-K IDEAYA Biosciences, Inc. For: Dec 04
11/14
12:36 pm
idya
Form SCHEDULE 13G/A IDEAYA Biosciences, Inc. Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SCHEDULE 13G/A IDEAYA Biosciences, Inc. Filed by: JANUS HENDERSON GROUP PLC
11/4
04:04 pm
idya
Form 10-Q IDEAYA Biosciences, Inc. For: Sep 30
Low
Report
Form 10-Q IDEAYA Biosciences, Inc. For: Sep 30
11/4
06:09 am
idya
Form 8-K IDEAYA Biosciences, Inc. For: Nov 04
Low
Report
Form 8-K IDEAYA Biosciences, Inc. For: Nov 04
10/20
06:43 pm
idya
Form 8-K IDEAYA Biosciences, Inc. For: Oct 17
Low
Report
Form 8-K IDEAYA Biosciences, Inc. For: Oct 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
Q3/2019 9/30/2019 EPS -0.540 ZacksConsensus -0.670 ActVsEst 0.130 - Beat
47.4%
12/18 Form 8-K IDEAYA Biosciences, Inc. For: Dec 17 14.3%
3/24 Q4/2019 12/31/2019 EPS -0.530 ZacksConsensus -0.570 ActVsEst 0.040 - Beat 12.0%
12/19 Form 3 IDEAYA Biosciences, Inc. For: Dec 17 Filed by: YARNO WENDY L 11.8%
4/7 Form 8-K IDEAYA Biosciences, Inc. For: Apr 06 10.9%
9/9 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
11/19 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 8.9%
4/6 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 8.5%
10/31 IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma 7.9%
1/10 IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ 7.5%
12/18 Form 8-K IDEAYA Biosciences, Inc. For: Dec 17 14.3%
3/24 Q4/2019 12/31/2019 EPS -0.530 ZacksConsensus -0.570 ActVsEst 0.040 - Beat 12.0%
12/19 Form 3 IDEAYA Biosciences, Inc. For: Dec 17 Filed by: YARNO WENDY L 11.8%
4/7 Form 8-K IDEAYA Biosciences, Inc. For: Apr 06 10.9%
9/9 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
11/19 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 8.9%
4/6 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 8.5%
10/31 IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma 7.9%
1/10 IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ 7.5%
TOP News Decliners
11/20
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress
-23.8%
3/11 IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities -20.3%
5/22 Form CERT IDEAYA Biosciences, Inc. -20.1%
8/1 Form 4 IDEAYA Biosciences, Inc. For: Jul 30 Filed by: Hata Yujiro S -11.6%
10/17 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $17.00 price target on the stock. -10.7%
1/16 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
4/1 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.0%
1/29 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.75 price target on the stock. -6.1%
2/6 Form SC 13G IDEAYA Biosciences, Inc. Filed by: CANAAN X L.P. -4.9%
11/13 Form 8-K IDEAYA Biosciences, Inc. For: Nov 13 -4.7%
3/11 IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities -20.3%
5/22 Form CERT IDEAYA Biosciences, Inc. -20.1%
8/1 Form 4 IDEAYA Biosciences, Inc. For: Jul 30 Filed by: Hata Yujiro S -11.6%
10/17 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $17.00 price target on the stock. -10.7%
1/16 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
4/1 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.0%
1/29 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.75 price target on the stock. -6.1%
2/6 Form SC 13G IDEAYA Biosciences, Inc. Filed by: CANAAN X L.P. -4.9%
11/13 Form 8-K IDEAYA Biosciences, Inc. For: Nov 13 -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: